KRYS - Pambiji Buku Bisnis Krystal Biotech

Krystal Biotech, Inc. (KRYS) relies on a unique therapeutic environment where the drug Vyjuvek occupies an exclusive niche with no alternatives. The company's operations involve compliance with ESG standards regarding laboratory waste disposal and logistics optimization. This chart shows the market price reaching 1.35, confirming the success of the strategy to implement innovative gene therapy to capture the rare skin pathology segment.

KRYS Kapitalisasi Buku Krystal Biotech Corp. (04.07.2022 - 28.10.2026)

Rincian metrik lan analitis perusahaan Krystal Biotech (KRYS)

- rega lan prakiraan konsensus rega:

Rega bursa Krystal Biotech Corp.|KRYS - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar Krystal Biotech Inc|KRYS - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku Saham Krystal Biotech|KRYS - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku krystalbio.com|KRYS - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Krystal Biotech, Inc.|KRYS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Krystal Biotech Inc|KRYS - Utang perusahaan|Utang marang nilai buku Krystal Biotech Inc|KRYS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Krystal Biotech

Pambiji fundamental:KRYS - Krystal Biotech Corp.

To balance operational risks and returns, it is essential to evaluate the net asset value of Krystal Biotech, Inc. (KRYS) minus all liabilities. Since the success of gene therapy depends on regulators rather than economic cycles, the book value capital trend reflects the business's actual material base, confirming its high macro-resilience and internal protection against market downturns.

Analisis pesaing Krystal Biotech, Inc.